Presentation — Navigating Early Phase CNS-Active Drug Development with Dr. Beatrice Setnik, CSO скачать в хорошем качестве

Presentation — Navigating Early Phase CNS-Active Drug Development with Dr. Beatrice Setnik, CSO

In this presentation originally presented at the ACCP Annual 2020 Meeting, Altasciences' Dr. Beatrice Setnik, Chief Scientific Officer, discusses how to navigate early phase drug development for central nervous system (CNS) active drugs. The presentation focuses on the following: Risk/benefit evaluations for CNS- active drugs and cannabinoids Regulatory considerations and requirements The importance of including assessments to receive safety information How and when to evaluate Human Abuse Potential (HAP) and physical dependence potential How drugs are scheduled Early development of clinical trials for CNS drugs are complex and require in-depth clinical expertise, but by the end of this presentation, you'll be all caught up on CNS drug development. About Our CNS and HAP Capabilities: Altasciences is a leader in the field of early phase clinical conduct for CNS trials. Our team has conducted over 100 opioid bioequivalence studies and conducted over 35 HAP and substance abuse studies in the last 5 years. Learn more about our CNS expertise: https://bit.ly/3j4Nkb2 Learn more about our experience with Human Abuse Potential (HAP) studies: https://bit.ly/3gkDIqL About Us: Altasciences is an integrated drug development solution company, offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to their preclinical and clinical study needs. From lead candidate selection to proof of concept, we offer one-stop integrated formulation, preclinical and clinical manufacturing and analytical services. Helping sponsors get better drugs to the people who need them, faster. Visit our website to learn more: https://www.altasciences.com/ #Altasciences #ScientificResearch #Pharmacology #ClinicalTrials #ClinicalResearch